Is intrathecal or intraventricular therapy with polymyxins or aminoglycosides still needed to improve the outcome of post-neurosurgical extensively/multidrug-resistant Gram-negative bacteria-related meningitis/ventriculitis in the current era of novel beta-lactams and beta-lactam/beta-lactamase inhibitor combinations?

Subjects

Subjects :

Humans
Treatment Outcome
Gram-Negative Bacteria drug effects
beta-Lactams therapeutic use
beta-Lactams administration & dosage
beta-Lactamase Inhibitors therapeutic use
beta-Lactamase Inhibitors administration & dosage
Anti-Bacterial Agents therapeutic use
Anti-Bacterial Agents administration & dosage
Drug Resistance, Multiple, Bacterial
Gram-Negative Bacterial Infections drug therapy
Gram-Negative Bacterial Infections microbiology
Cerebral Ventriculitis drug therapy
Cerebral Ventriculitis microbiology
Polymyxins therapeutic use
Polymyxins administration & dosage
Meningitis, Bacterial drug therapy
Meningitis, Bacterial microbiology
Injections, Spinal
Aminoglycosides therapeutic use
Aminoglycosides administration & dosage

Details

Language :

English

ISSN :

1872-7913

Volume :

63

Issue :

6

Database :

MEDLINE

Journal :

International journal of antimicrobial agents

Publication Type :

Editorial & Opinion

Accession number :

38643849

Full Text :

https://doi.org/10.1016/j.ijantimicag.2024.107177